ES2641779T3 - Derivados de estradiol 6-sustituidos y métodos de uso - Google Patents

Derivados de estradiol 6-sustituidos y métodos de uso Download PDF

Info

Publication number
ES2641779T3
ES2641779T3 ES09759335.4T ES09759335T ES2641779T3 ES 2641779 T3 ES2641779 T3 ES 2641779T3 ES 09759335 T ES09759335 T ES 09759335T ES 2641779 T3 ES2641779 T3 ES 2641779T3
Authority
ES
Spain
Prior art keywords
ch2n
ndc
ch2nh2
compounds
estrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09759335.4T
Other languages
English (en)
Spanish (es)
Inventor
James Yarger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endece LLC
Original Assignee
Endece LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endece LLC filed Critical Endece LLC
Application granted granted Critical
Publication of ES2641779T3 publication Critical patent/ES2641779T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
ES09759335.4T 2008-06-04 2009-06-03 Derivados de estradiol 6-sustituidos y métodos de uso Active ES2641779T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/132,857 US8168621B2 (en) 2005-09-30 2008-06-04 6-substituted estradiol derivatives and methods of use
US132857 2008-06-04
PCT/US2009/046120 WO2009149176A1 (en) 2008-06-04 2009-06-03 6-substituted estradiol derivatives and methods of use

Publications (1)

Publication Number Publication Date
ES2641779T3 true ES2641779T3 (es) 2017-11-13

Family

ID=41398499

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09759335.4T Active ES2641779T3 (es) 2008-06-04 2009-06-03 Derivados de estradiol 6-sustituidos y métodos de uso

Country Status (13)

Country Link
US (2) US8168621B2 (enExample)
EP (1) EP2300016B1 (enExample)
JP (1) JP5727370B2 (enExample)
KR (1) KR101769152B1 (enExample)
CN (1) CN102076343B (enExample)
AU (1) AU2009256237B2 (enExample)
BR (1) BRPI0913632A2 (enExample)
CA (1) CA2726364C (enExample)
DK (1) DK2300016T3 (enExample)
ES (1) ES2641779T3 (enExample)
MX (1) MX2010013288A (enExample)
NO (1) NO2300016T3 (enExample)
WO (1) WO2009149176A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002342335B2 (en) * 2001-05-16 2006-02-02 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
US10174070B2 (en) * 2005-09-30 2019-01-08 Endece Llc 6-substituted estradiol derivatives and methods of use
US20090028895A1 (en) * 2007-07-27 2009-01-29 Smith Walter P Methods and compositions for reducing facial lines and wrinkles
MX343059B (es) * 2010-09-14 2016-10-24 Endece Llc Derivados de desmetil-estradiol sustituido en 6 como agonistas de er-beta selectivos.
CN106420767A (zh) * 2011-03-21 2017-02-22 安德斯有限责任公司 用于神经轴突的髓鞘再生的6‑取代的雌二醇衍生物
US11624095B2 (en) 2017-09-27 2023-04-11 Case Western Reserve University Method of quantifying HIV reservoirs by induced transcription based sequencing
US20210024568A1 (en) * 2019-07-23 2021-01-28 Endece Llc Methods for modulation of lipoprotein lipase and apolipoprotein c2 expression and/or activity in the treatment of peripheral and central nervous system tissue disease states

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL122154C (enExample) 1963-10-18
GB8517360D0 (en) 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
GB8615092D0 (en) * 1986-06-20 1986-07-23 Erba Farmitalia Androst-4-ene-317-diones
GB8801697D0 (en) 1988-01-26 1988-02-24 Erba Farmitalia Improvements in synthesis of 6-methylene derivatives of androsta-1 4-diene-3 17-dione
US4904950A (en) 1988-11-04 1990-02-27 Medical Data Electronics, Inc. Telemetry digital subcarrier demodulator
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
JPH07215992A (ja) 1993-12-07 1995-08-15 Teikoku Hormone Mfg Co Ltd ６−又は７−置換アンドロスタ−１，４−ジエン誘導体
DE19633349A1 (de) 1996-08-19 1998-02-26 Sigma Tau Ind Farmaceuti Neue 6-Hydroxy- und 6-Oxo-androstan-Derivate, die auf das kardiovaskuläre System wirken und pharmazeutische Zusammensetzungen, die diese enthalten
CA2339835C (en) * 1998-08-11 2008-12-16 Entremed, Inc. Use of estrogenic compounds as anti-fungal agents
US6784170B2 (en) * 2000-02-11 2004-08-31 Sri International Synthesis of anti-estrogenic and other therapeutic steroids from 21-hydroxy-19-norpregna-4-en-3-one
IT1317031B1 (it) 2000-05-17 2003-05-26 Sigma Tau Ind Farmaceuti Procedimento migliorato per la preparazione di (e,z)3-(2-amminoetossimmino)-androstano-6, 17-dione e di suoi analoghi.
WO2002022645A2 (en) 2000-09-14 2002-03-21 Accelerated Pharmaceuticals, Inc. Method of making 7alpha-methyl-11beta-methoxy estradiol and related compounds with estrogenic activity
WO2005030120A2 (en) 2003-05-28 2005-04-07 Entremed, Inc. Antiangiogenic agents
US8088758B2 (en) * 2003-11-12 2012-01-03 Abbott Products Gmbh 17β-hydroxysteroid dehydrogenase type I inhibitors
ATE548375T1 (de) 2004-01-16 2012-03-15 Cedarburg Pharmaceuticals Inc Exemestan und zwischenprodukte davon und verfahren zu dessen herstellung
US7419972B2 (en) * 2004-07-02 2008-09-02 Schering Ag 2-substituted estra-1,3,5(10)-trien-17-ones as inhibitors of 17β-hydroxy steroid dehydrogenase type 1
US20080119447A1 (en) * 2005-09-30 2008-05-22 James Yarger 6-alkoxyalkyl estradiol derivatives and methods of use
CN101312743A (zh) 2005-09-30 2008-11-26 安德西有限公司 (s)-6-甲基氧杂烷基依西美坦化合物及相关使用方法
TWI392682B (zh) 2006-04-13 2013-04-11 Sigma Tau Ind Farmaceuti 作為心血管疾病的治療藥物之雄甾烷和雄甾烯的胺基衍生物

Also Published As

Publication number Publication date
US20120270817A1 (en) 2012-10-25
US8168621B2 (en) 2012-05-01
JP5727370B2 (ja) 2015-06-03
EP2300016B1 (en) 2017-08-09
KR20110019767A (ko) 2011-02-28
WO2009149176A1 (en) 2009-12-10
AU2009256237B2 (en) 2015-11-26
CA2726364C (en) 2016-10-11
DK2300016T3 (en) 2017-09-18
EP2300016A1 (en) 2011-03-30
JP2011522825A (ja) 2011-08-04
US20080312202A1 (en) 2008-12-18
CN102076343B (zh) 2015-04-01
US8629130B2 (en) 2014-01-14
AU2009256237A1 (en) 2009-12-10
MX2010013288A (es) 2010-12-21
EP2300016A4 (en) 2012-01-18
CA2726364A1 (en) 2009-12-10
NO2300016T3 (enExample) 2018-01-06
KR101769152B1 (ko) 2017-08-17
BRPI0913632A2 (pt) 2017-01-24
CN102076343A (zh) 2011-05-25

Similar Documents

Publication Publication Date Title
Schaiquevich et al. Treatment of retinoblastoma: what is the latest and what is the future
Nagelkerke et al. Hypoxia stimulates migration of breast cancer cells via the PERK/ATF4/LAMP3-arm of the unfolded protein response
ES2613098T3 (es) Compuestos de éter de bisfenol fluorado y métodos para su uso
Wang et al. Melatonin downregulates nuclear receptor RZR/RORγ expression causing growth-inhibitory and anti-angiogenesis activity in human gastric cancer cells in vitro and in vivo
KR101774652B1 (ko) 암 줄기세포 치료용 조성물
JP2018513123A (ja) Ｒｏｒガンマ阻害剤を用いてがんを治療するための方法
EP2678009B1 (en) Cystamine analogues for the treatment of parkinson's disease
Zhang et al. Effects and significance of formononetin on expression levels of HIF-1α and VEGF in mouse cervical cancer tissue
Ma et al. RETRACTED ARTICLE: Silencing of Long Non-Coding RNA-HCG18 Inhibits the Tumorigenesis of Gastric Cancer Through Blocking PI3K/Akt Pathway
Zhang et al. Protease-activated receptor-2 induces expression of vascular endothelial growth factor and cyclooxygenase-2 via the mitogen-activated protein kinase pathway in gastric cancer cells
JP6997919B2 (ja) がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用
JP5727370B2 (ja) ６−置換エストラジオール誘導体および使用方法
Caggiano et al. UCP2 and pancreatic cancer: conscious uncoupling for therapeutic effect
BR112021007237A2 (pt) métodos para o tratamento de uma vasculopatia em um indivíduo e para o tratamento de um transtorno do tecido conjuntivo em um indivíduo, kit, e, composição farmacêutica para o tratamento de uma vasculopatia
CN104837814B (zh) 新型化合物及其用途
Liu et al. MicroRNA-708 inhibits the proliferation and chemoresistance of pancreatic cancer cells
JP2016501845A (ja) 前立腺がんを処置するための方法
US20180305305A1 (en) 2-beta-naphthyl-acetic acid analogs as akr1c3 inhibitors and methods of using same
Liu et al. The effect and mechanism of celecoxib in hypoxia-induced survivin up-regulation in HUVECs
Zhang et al. BENC-511, a novel PI3K inhibitor, suppresses metastasis of non-small cell lung cancer cells by modulating β-catenin/ZEB1 regulatory loop
JP5290189B2 (ja) ６−アルコキシアルキルエストラジオール誘導体およびその使用
JP2017535584A (ja) エストロゲン受容体調節薬
Zhao et al. Association between integrin-linked kinase and hyperthermia in oral squamous cell carcinoma
CN116036094B (zh) 一种Rab13基因和EGFR蛋白表达的抑制剂及应用
JP2021525809A (ja) プロドラッグおよびその医学的使用